Androgen ablation therapy is currently the primary treatment for metastatic prostate cancer. Unfortunately, in nearly all cases, androgen ablation fails to permanently arrest cancer progression. As androgens like testosterone are withdrawn, prostate cancer cells lose their androgen sensitivity and begin to proliferate without hormone growth factors. In this study, we constructed and analyzed a mathematical model of the integration between hormone growth factor signaling, androgen receptor activation, and the expression of cyclin D and Prostate-Specific Antigen in human LNCaP prostate adenocarcinoma cells. The objective of the study was to investigate which signaling systems were important in the loss of androgen dependence. The model was formulated as a set of ordinary differential equations which described 212 species and 384 interactions, including both the mRNA and protein levels for key species. An ensemble approach was chosen to constrain model parameters and to estimate the impact of parametric uncertainty on model predictions. Model parameters were identified using 14 steady-state and dynamic LNCaP data sets taken from literature sources. Alterations in the rate of Prostatic Acid Phosphatase expression was sufficient to capture varying levels of androgen dependence. Analysis of the model provided insight into the importance of network components as a function of androgen dependence. The importance of androgen receptor availability and the MAPK/Akt signaling axes was independent of androgen status. Interestingly, androgen receptor availability was important even in androgen-independent LNCaP cells. Translation became progressively more important in androgen-independent LNCaP cells. Further analysis suggested a positive synergy between the MAPK and Akt signaling axes and the translation of key proliferative markers like cyclin D in androgen-independent cells. Taken together, the results support the targeting of both the Akt and MAPK pathways. Moreover, the analysis suggested that direct targeting of the translational machinery, specifically eIF4E, could be efficacious in androgen-independent prostate cancers.
Citation: Tasseff R, Nayak S, Salim S, Kaushik P, Rizvi N, Varner JD (2010) Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems. PLoS ONE 5(1): e8864. https://doi.org/10.1371/journal.pone.0008864
Editor: Kumar Selvarajoo, Keio University, Japan
Received: September 8, 2009; Accepted: December 22, 2009; Published: January 28, 2010
Copyright: © 2010 Tasseff et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors acknowledge the generous financial support of the Office of Naval Research (#N000140610293) to JDV, the support of SN, and the gracious financial support of RT by a National Science Foundation IGERT Nonlinear Systems Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Prostate cancer is the most common cancer in men and the second leading cause of cancer-related death in the United States . It has been known since the 1940s that androgens, such as testosterone, are required for prostate cancer growth . Accordingly, androgen ablation in combination with radiation or traditional chemotherapy remains the primary non-surgical treatment for androgen-dependent prostate cancer. Androgen ablation initially leads to decreased tumor growth and reduced secretion of biomarkers such as Prostate Specific Antigen (PSA) –. However, in nearly all cases androgen ablation fails to permanently arrest cancer progression. As testosterone is withdrawn, malfunctioning prostate cells lose their sensitivity to androgen and begin to proliferate without hormone growth factor signals. These testosterone insensitive cells can then lead to Androgen-Independent Prostate Cancer (AIPC) . The AIPC phenotype is closely related to metastasis and decreased survival. Unfortunately, current treatments for metastatic AIPC have demonstrated only modest survival advantages . Thus, an effective therepy for metastatic AIPC represents an unmet medical need and an ideal target for systems biology.
AIPC is characterized by androgen action in the absence of androgen stimulation. At the core of androgen action is the regulation of Androgen Receptor (AR) by hormones such as testosterone. AR is a cytosolic steroid hormone receptor belonging to the superfamily of ligand activated transcription factors. Other members of this family include Vitamin A/D, estrogen, progesterone and thyroid hormone receptors , . In healthy prostate epithelial cells, androgens activate AR and drive an AR-dependent gene expression program. Sexual androgens such as testosterone typically circulate in the blood, bound to proteins such as the Sex Hormone Binding Globulin (SHBG) protein. Free testosterone enters prostate cells where the 5-reductase enzyme converts it to activated dihydrotestosterone (DHT) . Both cytosolic testosterone and DHT can bind AR, however DHT has a higher affinity for AR. Binding of DHT to AR promotes cytosolic AR activation and the translocation of activated AR to the nucleus. Nuclear AR drives the expression of target genes including PSA by binding to AR-responsive promoter elements , . Because of its ligand dependence, one would expect AR activation and AR-driven gene expression to be absent without hormone stimulation. However, AIPC often has higher PSA expression and increased cell-proliferation compared to its androgen-dependent counterpart even without stimulation , .
AIPC's increased proliferation and PSA secretion in the absence of androgen suggests a failure in the regulation of androgen receptor activation. Feldman and Feldman reviewed several possible AR regulatory pathways perhaps responsible for androgen action in the absence of hormone stimulation . One hypothesis, referred to as the hypersensitivity pathway, suggests that AR may be more sensitive to androgen in AIPC. This would allow AR activation and AR-driven gene expression at much lower levels of extracellular testosterone signals. Another hypothesis, referred to as the promiscuous pathway, suggests that AR can be activated by non-androgen antagonists. A third hypothesis, explored here, suggests that AR can be activated by other pathways, for example, the Mitogen Activated Protein Kinase (MAPK) cascade. Several studies support this cross-talk hypothesis, sometimes referred to as the outlaw pathway. Culig et al. showed in DU-145 human prostatic tumor cells that growth factors e.g., IGF-I, KGF, and EGF could drive AR activation without androgen . Nazareth and Weigel showed in human prostate PC-3 cells that AR could also be activated by the protein kinase A activator, forskolin in the absence of androgen . Other studies have suggested a connection between Her2 induced activation of the primary MAPK cascade and AR activation . For example, Her2 overexpression was positively correlated with diminished sensitivity to androgen ablation, increased AR dependent PSA expression, increased AR activation, increased tumor mass and shortened tumor latency , –. Thus, one would expect regulators of Her2 activation, for example the different forms of the 100 kDa glycoprotein Prostatic Acid Phosphatase (PAcP), could be important factors in androgen dependence and tumor grade –. Intracellular PAcP (cPAcP) whose expression is AR responsive, downregulates Her2 by dephosphorylation. On the other had, secreted PAcP (sPAcP) promotes modest Her2 activation by an unknown mechanism .
The objective of this study was to determine which signaling components were important in AI versus AD LNCaP cells. Toward this objective, we constructed and analyzed a mechanistic mathematical model of the androgen response of three different LNCaP prostate adenocarcinoma sub-lines. We investigated MAPK-dependent outlaw activation of AR in AD (C-33), mid-range (C-51) and AI (C-81) LNCaP cells , . Our network model included: nuclear hormone and transmembrane growth factor receptor activation; transcriptional activity via the MAPK subsystem – together with outlaw activation of AR via MAPK , ; PI3K/AKT/TOR mediated translation initiation , ; the transcriptional and translational regulation of PSA, cyclin D and PAcP expression , ; and the regulation of Her2 activity by PAcP  (Fig. 1). The network described 212 species and 384 interactions (Table S1). Transcription and translation were modeled using elementary reactions based on literature (supplemental materials). Constitutive and regulated expression of PSA, cyclin D and the two forms of PAcP were considered in the model. The total level of all other model proteins was constant. We modeled the molecular interactions using mass action kinetic processes within an ordinary differential equation (ODE) framework. ODEs are a common method of modeling biological pathways and have been used to model a range of signal transduction processes , –. Mass action kinetics have also been used extensively, for example, to model receptor tyrosine kinase signaling , blood coagulation , pain networks  or Toll like receptor signaling , . They have also been a key component in the success of perturbation-response approaches which have shown that simple linear rules often govern the response behavior of biological networks . The ODE model was deterministic and captured only population averaged behavior. While we assumed spatial homogeneity, we differentiated between cytosolic and membrane localized processes. We used mass-action kinetics to describe the rate of each molecular interaction. Thus, the 384 kinetic model parameters were mainly association, dissociation or catalytic rate constants. With one exception, model parameters were estimated and validated using LNCaP training data taken from literature sources (Table S2). However, we were unable to estimate unique model parameters. Instead, we estimated a family or ensemble of parameters that was consistent with the training data. The ensemble allowed us to estimate the model uncertainty associated with the many poorly characterized parameters. We analyzed the model ensemble to better understand which architectural features were important in androgen dependent versus independence cells.
The model architecture was formulated by aggregating molecular modules into a single network (see insert for high level details). The model describes growth factor and hormone induced expression of cyclin D, PSA and the two forms of PAcP. The complete list of molecular interactions that comprise the model (along with kinetic parameter values) are given in Table S1.
Estimating the Ensemble of Prostate Model Parameters
Signal transduction models often exhibit complex behavior –. It is often not possible to identify model parameters, even with extensive training data . Thus, despite identification standards  and the integration of model identification with experimental design , parameter estimation remains challenging. In this study, an ensemble of plausible model parameters was estimated from AI and AD LNCaP sub-clones. Ensemble approaches have successfully addressed uncertainty in systems biology and other fields like weather prediction , –. Their central value is the ability to constrain model predictions despite uncertainty. For example, Sethna and coworkers showed in a model of growth factor signaling that predictions were possible using ensembles despite incomplete parameter information (sometimes only order of magnitude estimates) . They further showed that model ensembles were predictive using many different mathematical models .
The 420 unknown model parameters (384 kinetic constants and 36 non-zero initial conditions) were estimated using 14 time-series and steady-state training sets taken from literature sources (Table S2). The parameter identification procedure used a maximum likelihood random-walk strategy with a correlation constraint to identify a diverse family of likely parameter sets (Fig. 2C). We generated 3210 possible parameter sets and selected 107 of these for inclusion in the final ensemble. The selection was made to minimize the correlation between possible sets (materials and methods). The majority of parameters had a Coefficient of Variation (CV) of greater than 100%. Thus, although the model qualitatively recapitulated the training data, many of the parameters were poorly constrained (Fig. 2B). However, parameters involved with key features such as cyclin-D and PSA expression were relatively well constrained (CV50%). The low deviation of these parameters could be attributed to the abundance of PSA/cyclin D training data. Alternatively, it may suggest that these mechanisms had a large impact on model behavior. A single network structure described both Androgen Dependent (AD) and Androgen Independent (AI) training data with only two experimentally justified parameter changes. The parameters controlling the expression rate of cellular PAcP (cPAcP) and secreted PAcP (sPAcP) were reduced by a factor of 0.01 and 0.5, respectively, for the C-81 and C-51 cell-lines compared to C-33 (Fig. 2A). The PAcP expression scaling factors were chosen to correspond with measured steady-state PAcP expression ratios for the different cell-lines . The kinetic parameters and non-zero initial conditions for C-33 are given in Table S1 and Table S3, respectively.
A: Steady state PSA level as a function of cPAcP and sPAcP expression. The circles represent the values used to model the C-51 and C-81 LNCaP clones. All values are relative to C-33. B: Coefficient of Variation (CV; standard deviation of a parameter relative to its mean value) for the parameter ensemble used in this study. A small CV suggested a parameter was tightly constrained by the training data used for model identification. The parameters with the three smallest CVs are listed. C: Parameter identification strategy. Multiple monte-carlo trajectories were used to randomly explore parameter space. The simulation error and the correlation between parameter sets was used to generate the family of parameter sets used in the simulation study.
The Ensemble of AI/AD Lncap Models Recapitulated Androgen Action and the Activity of the Outlaw Pathway
AR can be activated by both hormone dependent and independent pathways. In this study, we considered both the traditional hormone dependent and MAPK mediated AR activation. We selected training data sets to constrain each mode of AR activation and the subsequent AR-driven gene expression program. The data of Lee et al., was used to constrain the relationship between PSA expression and AR activation in AI and AD cells . Activated AR was modeled as both a transcriptional activator of PSA expression  and a transcriptional represser of PAcP expression . The model recapitulated the qualitative features of PSA expression at the protein level for C-81 and C-33 (Fig. 3B). Additionally, the basal and increased level of PSA mRNA following Her2 overexpression in C-33 was also well described (Fig. 4). The PSA mRNA data was taken from a separate LNCaP study . The C-33 simulations recapitulated the observed lower PSA expression (4 fold) compared to C-81 in the absence of androgen (Fig. 3B, initial point). Following DHT stimulation (10nM at t = 1 hr) PSA expression increased for both clones. However, the increase was more significant for C-33 (Fig. 3B). The study of Meng et al. was used to constrain the relationship between AR activation and PAcP expression . The addition of DHT to C-33 cells decreased PAcP expression and increased Her2 phosphorylation (Fig. 3A).
A: Her2 phosphoralation (circles) and cPAcP expression (squares) for C-33 cells following the addition of DHT. Experimental data reproduced from Meng et al. . B: PSA expression following the addition of DHT to C-81 (squares) and C-33 (circles) LNCaP clones. Experimental data reproduced from Lee et al. . The shaded region in each plot denotes one standard deviation centered about the ensemble mean (line).
Her2 overexpression was modeled as a 50% increase in the expression rate of Her2. Bars denote the mean PSA mRNA level over the parameter ensemble while error bars denote one ensemble standard deviation. The experimental PSA mRNA data was adapted (replotted) from .
The model recapitulated the positive feedback between Her2 induced MAPK activation and androgen action. Several studies have demonstrated that MAPK can activate AR in the absence of hormone stimulation. Activated AR transcriptionally down-regulates cPAcP expression which in turn increases Her2 activation. Both Her2 dimerization along with the traditional EGFR-growth factor pathway can activate MAPK, leading to a positive feedback loop. However, typical growth factor induced MAPK activation is transient whereas de-regulated Her2 induced MAPK activation is persistent. The MAPK module in the model described both activation pathways. Growth factor dependent MAPK activation was constrained by dynamic measurements of phosphorylated ERK (ERKpp) levels following stimulation of EGFR with 8nM EGF (Fig. 5D). The EGF induced ERKpp data was taken from HeLa cells . However, we expect transient EGF-induced MAPK activation in LNCaP cells will be qualitatively similar to HeLa given the conserved nature of mitogenic signaling. We constrained Her2 induced MAPK activation using cyclin D protein expression data in C-33 and C-81 cells without androgen following PAcP expression (Fig. 5C). Cyclin D expression was coupled to ERK through the ETS and AP1 transcription factors, both of which activate cyclin D expression . Her2 induced MAPK activation led to a persistent ETSp signal compared to ETS activation following EGFR-induced MAPK activation (Fig. 5D, inset). Nominally, C-33 cells have lower cyclin D expression compared to C-81 (Fig. 5C, lane 1 and 4). The difference in cyclin D expression between C-33 and C-81 cells was qualitatively consistent with increased C-81 proliferation . While the expression of cPAcP in C-81 reduced cyclin D levels (Fig. 5C, lane 2), sPAcP expression resulted in no change (Fig. 5C, lane 3). Furthermore, the model predicted a dose dependent increase in C-33 cyclin D levels 24 hours after addition of DHT (Fig. 6A). Although the cyclin D increase is only notable in response to high levels of DHT (10 or 100nM) the prediction is qualitatively consistent with experimental data not included in the ensemble calculations .
A: Effect of HER2 and MEK overexpression on LNCaP C-33 steady state PSA levels. The inhibition of MEK blocks the effect HER2 overexpression. Experimental data adapted from Lee et al. . B: Effect of HER2 and MEK inhibition on LNCaP C-33 steady state PSA levels. The inhibition of either HER2 or MEK blocks high AIPC PSA levels. Experimental data adapted from Lee et al. . C: Effect of PAcP isoforms on LNCaP steady state cyclin D levels. Experimental data adapted from Lingappa and coworkers (Prosetta Corporation, unpublished data). D: Transient activation of ERK via ligand dependent EGF signaling (8nM EGF at t = 60s) in HeLa cells. The HeLa data was reproduced from . Inset: Simulated phosphorylated ETS (ETSp) levels following the addition of 8nM EGF in the presence and absence of Her2. Her2 activation drives a sustained MAPK signal which in turns sustained ETS activation. The shaded region denotes one standard deviation centered about the ensemble mean (line).
A Ensemble prediction of cyclin D expression following the addition of DHT at 1 hour to C-33 clones. The ensemble predicted a dose dependent increase of cyclin D at 24 hours after DHT addition. Experimental data was adapted from Barnes-Ellerbe et al. . B Predicted effect of an AR knockdown on PSA expression following the addition of androgen at 1 hour to C-33 wild-type and C-33 AR knock-down clones. The ensemble predicted an approximate 50% decrease in androgen stimulated PSA expression due to AR knock-down 72 hours after treatment. Experimental data was reported by Eder et al. . The error bar denotes one standard deviation centered about the ensemble mean.
To further constrain the relationship between MAPK, Her2 and AR activation, we used the Her2 perturbation study of Lee et al.  in the ensemble calculations. Because the perturbation magnitudes were not reported, we assumed 50% for all changes. Where possible, this assumption was validated by analyzing the corresponding Western blots using the GelEval software package (v1.22, Frog Dance Software). The 50% perturbation magnitude was approximately consistent with the published blots. A 50% increase in Her2 led to an approximately 50% increase in PSA expression in C-33 without androgen (Fig. 5A, lanes 1 and 3). While a 50% decrease in Her2 in C-81 led to a similar decrease in PSA secretion (Fig. 5B, lanes 1 and 2). Further disruption of Her2 effectively blocked PSA expression in C-81 without androgen (Fig. 5B, lane 3). A 50% reduction of MEK, one of the three primary protein kinases in MAPK, resulted in reduced PSA expression in C-81 (Fig. 5B, lane 4). While a 50% increase of MEK in C-33 increased PSA expression by 5-fold (Fig. 5A, lane 2). The combination of MEK inhibition and Her2 activation (50% increase in Her2 and a 50% decrease in MEK) decreased PSA expression in C-33 (Fig. 5A, lane 4). Furthermore, the model predicted an increase in C-33 PSA levels 72 hours after a 2nM addition of the androgen testosterone. Simulations performed with 10% of the AR initial condition predicted an approximate 50% decrease in testosterone stimulated PSA (Fig. 6B). The reduced PSA levels are consistent with reported experimental data on AR antisense knock-downs in androgen dependent LNCaP cells . This data was not included in the ensemble calculations. Taken together, the model replicated qualitative features of the relationship between MAPK, AR activation and androgen action. In addition, the qualitative agreement between model and experiments for PSA and cyclin D expression suggested that the transcription and translation subsystem models were operating correctly.
Sensitivity and Robustness Analysis Revealed Key Subsystems in AI and AD Cells
Sensitivity analysis identified interactions important in C-33, C-51 and C-81 cells (Fig. 7 and Table S4). We calculated overall State Sensitivity Coefficients (OSSCs) for the three LNCaP clones over the parameter ensemble (materials and methods). The OSSC values were ranked-ordered based on their absolute magnitude. The dissociation of AR from Heat Shock Proteins (HSP), components of the Akt signaling axis and MAPK activation were important (top 2% of sensitive interactions) irrespective of androgen status. Sequestered AR was unable to become activated by androgens or MAPK. Thus, increased AR-HSP dissociation promoted increased AR activation and AR-driven gene expression. Several components of the MAPK cascade were also important including Ras binding to GAP and Raf, and the dephosphorylation of ERK. The sensitivity of MAPK was not unexpected. ERK was critical to outlaw activation of AR. Moreover, ERK activation was modeled as being Ras dependent. We also found the Akt signaling axis to have components in the top 2% of sensitive interactions irrespective of androgen status. For example, the formation of PIP3, an early step in the PI3K/Akt signaling axis regulated by PTEN, was found to be highly sensitive in all clones. Looking beyond the upper 2% of sensitive interactions, additional common mechanisms were identified. These included AR interactions with DHT, recruitment of adapter molecules by Her2, activation of ERK by MEKpp and additional regulation of PIP3 formation by PTEN.
A: Comparison of the mean OSSC parameter ranks for the C-33 and C-81 LNCaP models. Large ranks indicate fragility. Points left of the 45 line are more important in C-33, while shifts to the right show increased importance in C-81. Points are organized by biological function. B: Comparison of the mean OSSC parameter ranks for translation mechanisms (including the role of Akt signaling in translation initiation) in C-33 versus C-81 LNCaP clones. The error bars indicate one standard deviation centered about the mean ensemble value. C: The final mechanism in PSA transcription becomes increasingly more robust w.r.t cancer aggressiveness, as indicated by a significant reduction in mean OSSC Rank. D: The final mechanism in PSA translation (translation termination) was increasingly fragile w.r.t cancer aggressiveness, as indicated by a significant increase in mean OSSC rank. The results indicate a shift in the bottle neck for generation of PSA from transcription to translation as prostate cancer cells lose their androgen dependence. The top and bottom of each box denote the 25th and 75th percentile of the OSSC rank over the parameter ensemble. The center line denotes the median value. Whiskers show the furthest observations and black crosses indicate outliers.
Translation interactions became more fragile while transcription became more robust with increasing androgen independence. Her2 auto-activation and Her2 cPAcP interactions were also increasingly important with increasing androgen independence. The difference in the importance of interactions in AI versus AD LNCaP clones was estimated by computing shifts in the sensitivity rankings (Table S5). In addition to considering C-33 and C-81, we analyzed a third clone, C-51, which was moderately androgen dependent. There were 117 statistically significant shifts (52 more and 65 less sensitive) between the C-81 and C-33 clones. However, only 14 shifts were larger than one standard above the mean shift. Of the 14 large shifts, 50% involved PSA and PAcP translation while the remainder were associated with Her2 and cPAcP. Conversely, PSA transcription became more robust with increasing androgen independence. Similarly, when comparing C-33 to C-51, PSA translation and Her2 activity became more sensitive with increasing androgen independence. Inspection of the importance of the final step in PSA transcription and translation among the individual models in the ensemble showed a shift away from transcription (Fig. 7C) toward translation (Fig. 7D) across the population of models. The increasing importance of translation was not limited to PSA, although PSA was the most significant example. Globally, 16 of the 52 interactions that were more sensitive in C-81 involved translation while only 4 of 52 involved transcription. No translation mechanisms became more robust in C-81 compared to C-33. Similar to PSA, translation of other key proteins such as cPAcP became more sensitive in C-81 versus C-33. Of the statistically significant shifts, 7/9 of the cPAcP translation interactions were more sensitive in C-81. Additionally, both mechanisms for the phosphorylation of 4E-BP1 by TOR kinase, a key step in translation initiation that liberates eIF4E, were also more importance in C-81. Taken together, the sensitivity analysis suggested that the fragility of the translational subsystem directly correlated to androgen independence.
To quantify the effects of perturbing key species in C-81 clones we preformed robustness analysis on four functional protein markers. The initial conditions of seven key protein species were altered by a factor of 10, .1 or 0 for knock-in, knock-down or knock-out perturbations, respectively. We then calculated the effect of these perturbation on cyclin D and PSA expression levels along with ERK and AR activation levels. Perturbation of Raf, MEK or ERK had similar effects on the functional markers with ERK being the most notable (Fig. 8, lanes 1, 2 and 3). Trivially, ERK perturbations directly effected ERK activation levels. However, more importantly, ERK perturbations greatly effected cyclin D expression levels. ERK knock-ins approximately doubled cyclin D while ERK knock-outs reduced cyclin D to less then one third of wild-type levels. The functional markers were robust to perturbations in AKT and TOR with differing effects on ERK activity and slight decreases in expression levels upon AKT or TOR knock-out (Fig. 8, lanes 4 and 5). Furthermore, the translation initiation factor eIF4E demonstrated a limiting reagent behavior in the expression of both cyclin D and PSA while perturbations in 4E-BP1 had little effect (Fig 8, lanes 6 and 7). However, the 4E-BP1 results could be an artifact of artificially high background levels of eIF4E as no direct eIF4E measurements were included in the training data. Knock-in simulations of eIF4E demonstrated an 8.7 and 5.2 fold increase in cyclin D and PSA expression. Reduction of eIF4E resulted in a 89% loss of expression and, full knock-out simulations predicted a complete loss of cyclin D and PSA.
The expression level of seven key proteins was altered by a factor of 10, .1 or 0 (knock-in, knock-down or knock-out) and robustness coefficients (area under the curve for the perturbed versus wild-type simulation) were calculated for cyclin D and PSA expression levels along with ERK and AR activation levels. Simulations were run for C-81, with the indicated perturbation, to approximate steady-state and 10nM of DHT was added for 72 hours. Ensemble mean values are reported.
The MAPK and Akt Pathways Synergistically Activated Cyclin D Expression
Complex systems composed of interacting subsystems can display emergent properties that are not explained by the individual subsystems alone . In cancer biology, it is common to speak of signal transduction pathways as if they were isolated. In reality, these components are highly interconnected and can interact in a variety of ways sometimes leading to unpredictable behavior. In this study, we explored whether the MAPK and Akt signaling axes synergistically activated the expression of cyclin D. We compared the steady-state cyclin D expression in Akt and ERK knock-outs with wild-type C-81 cells in the absence of androgens. At steady-state, the MAPK and Akt pathways synergistically () activated cyclin D expression in C-81 cells without androgen (Fig. 9A). Thus, steady-state cyclin D expression was greater in wild-type cells (Akt-ERK) than the linear combination of cyclin D expression in Akt-EKT and Akt-ERK cells. The above-additive (superlinear) cyclin D expression was statistically significant within a 95% confidence interval. However, the relatively large standard deviation suggested that cyclin D expression varied widely across the ensemble. To address this, we inspected every model in the ensemble and found that each predicted an above-additive increase in cyclin D expression (data not shown). Superlinear cyclin D expression may be the result of positive synergy between the MAPK and translation subsystems. To elucidate the underlying mechanisms responsible for synergy we expanded the analysis to include all modeled species (both proteins and protein complexes) and rates. Many functional network subunits demonstrated no statistically significant deviations from additive behavior (Fig. 9C, grey). However, 22 species (79 interactions) were negatively coupled to Akt/ERK (; Fig. 9B, red) while 14 species (37 interactions) had a positive synergy (; Fig. 9B, green). Synergy between the MAPK and Akt signaling subsystems negatively effected transcription factor activation. Phosphorylated ERK (ERKpp) activated AR (pAR), and the transcription factors AP1 and ETS all showed a below additive response (Fig. 9B). Conversely, positive synergy was almost exclusively limited to translation interactions. The binding of eIF4E, 40S and 60S ribosomes to form the mRNA initiation complex, elongation and termination steps all had positive synergy with ERK/Akt knockdowns (Fig. 9B).
A: The difference in steady state cyclin D expression (compared to the control) with the knock-in of Akt (left), ERK (center) and both (right). The predicted cyclin D levels were normalized by the basil C-81 steady state cyclin D level in each case. The error bars denote one standard deviation centered about the ensemble mean. The region denoted by the asterisks represents above-additive cyclin D expression. B: Species and interactions that demonstrated a positive (negative) synergy are shown as green (red) in the connectivity diagram. Species or interactions not effected are shown in grey. C: The full connectivity diagram qualitatively clustered in functional groups. Positive (negative) synergy are shown in green (red) in the connectivity diagram. Species or interactions not effected are shown in grey.
A critical milestone in prostate cancer progression is the onset of androgen independence. In this study, we formulated and analyzed an ensemble of mathematical models of the androgen response of AI and AD LNCaP prostate cancer epithelial cells. The model ensemble was identified using 14 different steady-state and dynamic data sets taken from literature. With the exception of one study, all the training data was generated in LNCaP cell-lines. We estimated which molecular subsystems were important in AI versus AD cells using sensitivity analysis. For example, the assembly and regulation of Her2 adapter complexes and the regulation of ERK were sensitive irrespective of androgen status. The dissociation of AR from HSP was also in the top 2% of sensitive interactions for both C-33 and C-81. On the surface, the importance of AR in C-81 was surprising as the proliferation of C-81 is androgen independent. However, AR can be activated independently of androgen, thus, the presence of androgen is not required for androgen action , . The differentiating factor between the AI and AD models described here was the expression rate of PAcP conformers. We demonstrated the ability of decreased PAcP expression to describe the PSA levels of increasingly androgen independent sub-lines. Moreover, interactions involving Her2 auto-phopshporylation, cPAcP availability and cPAcP phosphatase activity were significantly more fragile in C-81 versus C-33. These results suggest that the regulation of the phosphorylation state of Her2 by cPAcP may be a critical interaction controlling androgen action in the absence of hormone signals. Experimentally this has been demonstrated as forced expression of PAcP is sufficient to suppress C-81 xenograft tumor growth .
Model analysis suggested that translation interactions were more fragile and transcription more robust in AI versus AD cells. Globally, 16 of the 52 interactions that were more sensitive in C-81 involved translation while only 4 of 52 involved transcription. Moreover, no translation mechanisms became more robust in AI versus AD cells. The importance of translation in more aggressive cancers (increasing androgen independence) may be due, in-part, to synergies between the Akt and MAPK pathways. Simulations of ERK and/or Akt knockouts showed an above-additive response almost exclusively limited to translation upon the simultaneous reinstitution of Akt and ERK. In-vivo studies of AIPC have demonstrated positive synergies between the MAPK and Akt pathways. Gao et al. observed above-additive tumor growth rates in castrated and mock nude male mice upon the forced expression of constitutively active Akt and B-Raf . These experiments suggest that cell proliferation may be regulated by a complex integration of the MAPK and Akt signaling axes. Our robustness analysis suggested that independent perturbations in TOR and AKT may have little or no effect on AIPC. However, we observed the possibility of an inverse relationship between TOR and ERK activation. This suggests that if TOR or Akt were to be independently targeted, AKT might be a more suitable therapeutic target. Additionally, we observed that perturbations in Raf, MEK and ERK had a similar effect on cyclin D but not PSA expression, with ERK being more pronounced. Current therapeutics such as trastuzumab or gefitinib, which target either Her2 or EGFR respectively, have had little efficacy against hormone-refractory prostate cancers , . Our results suggest that a possible factor in their lack of effectiveness is that they fail to address synergy between growth factor signaling, MAPK activation and the Akt signaling axes. Our analysis also demonstrated that translation mechanisms were generally more sensitive in increasingly androgen independent models. The translation results suggest that the direct targeting of the translation machinery may be useful for the treatment of AIPC. Our robustness analysis identified eIF4E as a limiting reagent in the expression of both cyclin D and PSA in C-81 clones. Soni et al. demonstrated the effectiveness of directly targeting eIF4E in breast cancer. Down-regulation of eIF4E resulted in decreased cyclin D expression and decreased growth rate without the deleterious effect of inhibitors such as rapamycin which act further upstream . Previous modeling studies from our laboratory have also demonstrated the importance of translation beyond cyclin D . However, the current model has only a basic description of translation initiation. Moreover, translation parameters were only indirectly trained from the PSA mRNA and protein data. Thus, while the initial robustness and sensitivity results are encouraging more studies are needed.
Analysis of the ensemble of AI models suggested the Akt and MAPK pathways synergistically enhanced cyclin D expression by up-regulating translation. Cyclin D is expressed early in the cell cycle and a point of convergence in the proliferative action of multiple receptors . Many studies have identified a direct correlation between cyclin D regulation and prostate cancer, as well as breast and non-small cell lung cancer –. Balk et al. demonstrated that increased cyclin D expression in PTEN LNCaP cells following DHT addition was largely because of increased translation . PTEN loss and presumably the activation of Akt has been implicated with increased translation and the resistance to therapeutics which target Her2 and EGFR , . However, the underlying mechanism responsible for the increased translation in the Balk et al. study was not solely AKT dependent. Early translation activation was due to PI3K/Akt signaling but TOR activation at later time points was Akt independent. One key difference between the modeling and the Balk et al. study was the binding of activated AR with the regulatory subunit of PI3K. This interaction, which was not included in the model, was at least partially responsible for TOR activation and the eventual liberation of eIF4E. In addition to direct AR binding, PI3K (and subsequently TOR) can be activated through receptor adaptor complexes such as those associated with Her2. In the model, PI3K was activated by androgen (in the absence of growth factor) because of the down-regulation of cPAcP expression by activated AR. Upregulated PI3K then drove Akt dependent activation of TOR which led to enhanced liberation of eIF4E from 4E-BP1. Thus, while the initiating events driving TOR activation were different, the subsequent up-regulation of cyclin D translation was similar. This suggests that the model prediction of a complex synergy between interacting signaling axes may be valid. It also suggests a falsifiable hypothesis that cPAcP could be critical to enhanced translation following androgen stimulation.
The role of mechanistic mathematical modeling in drug design remains unclear. A common criticism of such techniques has been the poorly characterized effect of model uncertainty. Model uncertainty has two forms. Structural uncertainty is defined as uncertainty in the biology, while parametric uncertainty is defined as incomplete knowledge of parameter values. In this study, parametric uncertainty was minimized by considering a family of consistent models instead of a single best-fit but uncertain model. While model ensembles often poorly constrain individual parameter values, they may robustly constrain model predictions . Structural uncertainty was addressed by considering only molecular interactions supported by experimental evidence. However, the current model contained some abstracted pathways and should be expanded to include additional biology. For example, the analysis highlighted the importance of translation. However, the current model contains a limited description of initiation factor activation and the assembly of the 80S initiation complex. A more detailed translation interaction network could further refine which translation components were important in AI versus AD cells. Another example is the mechanism by which AR transcriptionally regulates the expression of target genes. In the current model we ignored the role of transcriptional co-regulators and assumed activated AR functioned alone. While this is a reasonable first approximation, well known co-repressors and activators  such as ARA70  should be included. The regulation and activity of these co-regulators may be different in AI versus AD cells and could enhance the list of differentially important targets. Additionally, a nuclear compartment and enhanced cell cycle and cell death subnetworks should be added to the model. These additional networks could be critical to understanding cell proliferation and survival effects in AI versus AD cells. For example, androgen and AR are known to regulate several components of the G1-phase of the cell cycle in prostate cells, not just cyclin D . Moreover, the model describes the activation of Akt in the context of translation initiation, but not its well know survival functions , . Lastly, given the importance of EGFR and Her2 induced MAPK activation in the current study and the therapeutic emphasis on receptor inhibition we plan to include a more complete receptor signaling network. Other receptors, IGFR and IL-6R have also been implicated in prostate cancer –. Understanding the signaling associated with these receptors and their downstream targets should be considered and will provide a better representation of how intra- extra-cellular communication drives cell fate decisions. Furthermore, the application of advanced sampling techniques may allow for a more exhaustive investigation of parameter space. For example, multi-objective optimization ensemble techniques could be used to balance conflicts in the training data . Additionally, understanding the topological details of the cost function in an extended parameter space could provide statistical information on kinetic rates and initial conditions. Other techniques, for example the calculation of the mutual information matrix, could also provide insight into correlations between model interactions. Also, computation of second order sensitivity coefficients would allow the identification of possible synergies in the model. Thus, we expect that deeper insight could be generated by extending the network structure and through the application of advanced model analysis tools.
Materials and Methods
Formulation and Solution of the Model Equations
The prostate model was formulated as a set of coupled Ordinary Differential Equations (ODEs):(1)The symbol denotes the stoichiometric matrix (). The quantity denotes the species concentration (). The term denotes the vector of reaction rates (). Each row in described a species while each column described the stoichiometry of network interactions. Thus, the element of , denoted by , described how protein was involved in rate . If , then protein was consumed in . Conversely, if , protein was produced by . Lastly, if , protein was not involved in rate .
We assumed mass-action kinetics for each interaction in the network. The rate expression for protein-protein interaction or catalytic reaction :(2)was given by:(3)The set denotes reactants for reaction . The quantity denotes the set of products for reaction . The term denotes the rate constant governing the qth interaction. Lastly, denote stoichiometric coefficients (elements of the matrix ). We treated every interaction in the model as non-negative. All reversible interactions were split into two irreversible steps. The mass-action formulation, while expanding the dimension of the prostate model, regularized the mathematical structure. The regular structure allowed automatic generation of the model equations. In addition, an analytical Jacobian () and matrix of partial derivatives of the mass balances with respect to the model parameters () were also generated. Mass-action kinetics also regularized the model parameters. Unknown model parameters were one of only three types, association, dissociation or catalytic rate constants. Thus, although mass-action kinetics increased the number of parameters and species, they reduced the complexity of model analysis. In this study, we did not consider intracellular concentration gradients. However, we accounted for membrane and cytosolic proteins by explicitly incorporating separate membrane and cytosolic protein species. We did not consider a separate nuclear compartment.
An approximate steady-state was used as the starting point ( hr) for all simulations presented in this study. For example, when calculating the response of LNCaP to the addition of DHT, we first ran the model to steady-state and then simulated the addition of DHT. Although no individual cell is likely to be at steady-state we assumed that steady-state was a reasonable approximation of the population average behavior of LNCaP cells growing in the exponential phase. The steady-state was estimated numerically by repeatedly solving the model equations and estimating the difference between two subsequent time points:(4)The quantities and denote the simulated concentration vector at time and , respectively. The quantity denotes the vector norm. In this study, we used hrs of simulated time and = 0.01 for all simulations.
Estimation of the Prostate Model Parameter Ensemble
An initial set of model parameters, denoted by , was chosen by hand to replicate the training data. The training data consisted of 14 time-series and steady-state data sets taken from literature sources (Table S2). The initial parameter guess was used to generate an ensemble of parameters that maximized the likelihood of describing the training data. The difference between the measured and simulated value of species at time or condition , denoted by and respectively, was quantified by the normalized mean squared error, :(5)where the sum was carried out over all species and observations . The quantities and denote the total number of observations and the measurement standard deviation of species at time or condition , respectively. If no experimental error was reported, we assumed a standard deviation equal to 10% of the reported observation. In cases where the quantification of the stimulus or observation was unclear an augmented error of 20%–100% was applied to compensate for the added uncertainty. is a scaling factor which is required when considering experimental data that is accurate only to a multiplicative constant (assumed here to be the case form immunobloting analysis). The scaling factor was chosen to minimize the normalized squared error between a given experiment and species :(6)Because of the scaling factor, the concentration units on simulation results were arbitrary (consistent with the arbitrary units on the majority of the training data). All simulation outputs reported in this study were scaled by the corresponding . There was insufficient training data to properly constrain the 420 model parameters. To account for parametric uncertainty, a monte-carlo approach similar to Battogtokh et al.  was used to generate an ensemble of parameters. Consider a set of model parameters . Let the likelihood that model simulations with parameters describe the training data be defined as:(7)where denotes the simulation error associated with parameter set . The quantity is a parameter used to tune the rate of acceptance. Further let the acceptance probability, , of a new parameter set, , be if and 1 otherwise. denotes the probability that will be accepted as for consecutive monte-carlo steps. Parameter sets were generated by applying a small additive random perturbation in log space:(8)where is a normally distributed random number with zero mean and variance . The perturbation was applied in log space to account for the large variation in parameter scales and to ensure positivity. Monte-carlo trajectories were generated starting from where 0.05 or 0.1 and 1 or 0.5. The autocorrelation function of each trajectory was calculated. The number of monte-carlo steps between parameter sets which were added to the ensemble was taken to be the number of steps after which the autocorrelation function dropped to 5% of its initial value. This was done to ensure independence between sets in the ensemble. To compensate for noise in the autocorrelation function an exponential fit was applied. The final ensemble contained 107 parameter sets, which produced an ensemble of 5.25.
Sensitivity Analysis of the Prostate Network
Overall State Sensitivity Coefficients (OSSC) were used to estimate which structural elements of the prostate network were sensitive . OSSC values were determined by first calculating the first-order sensitivity coefficients at time :(9)First-order sensitivity coefficients were computed by solving the matrix differential equation:(10)subject to the initial condition . In Eqn. 10, denotes the parameter index, denotes the number of parameters in the model, denotes the Jacobian matrix, and denotes the th column of the matrix of first-derivatives of the mass balances with respect to the parameter values (denoted by ). An analytical Jacobian and matrix of first-derivatives of the mass balances w.r.t the parameters:(11)were generated from the model equations. The quantity and denotes a point along the unperturbed model solution. The sensitivity equations required that we solve the model equations to evaluate the and matrices. Thus, we formulated the sensitivity problem as an extended kinetic-sensitivity system of equations :(12)where and . We solved the kinetic-sensitivity system for multiple parameters in a single calculation using the LSODE routine of OCTAVE (www.octave.org). The first-order sensitivity coefficients were then used to calculate the OSSC value for parameter :(13)The terms denote the number of time points considered and the state dimension of the model, respectively. To account for parametric uncertainty, OSSC values were calculated over the parameter ensemble. Parameters were ranked-ordered () based upon the magnitude of the OSSC value. Large values of indicated fragile or important interactions in the prostate network architecture. Conversely, small values of indicated robustness.
Each model in the ensemble was run to approximately steady state. At steady-state, 10nM DHT was added and the first order sensitivity coefficients were calculated for 100 seconds of simulated time. OSSC values were then calculated and the rank ordering determined. We collected interactions whose rank was at least one standard deviation above the mean rank calculated over all parameters. Highly ranked interactions were statistically significantly different between LNCaP clones if the null hypothesis could be rejected with 95% confidence via a t-test. To estimate significance, we performed a two variable unequal variance double tail t-test using the MATLAB (R) statistical toolbox (2007a, The Mathworks, Natick, MA).
Robustness Analysis of Functional Protein Markers
Robustness coefficients of the form:(14)were calculated to understand the regulatory connectedness of functional protein markers in the LNCaP network. The robustness coefficient is the ratio of the integrated concentration of a network output in the presence (numerator) and absence (denominator) of structural or operational perturbation. Here and denote the initial and final simulation time respectively. Simulations were taken of C-81 from approximate steady-state at , 10nM of DHT was added at 1 hour and was taken to be 72 hours after DHT addition. The network output was taken to be the network states. The quantity denotes the index for a marker or reference species while denotes the perturbation index, respectively. If , then the perturbation increases the output concentration. Conversely, if the perturbation decreases the output concentration. Lastly, if the perturbation does not influence the output concentration.
Calculation of Steady-State Synergy Coefficients
To understand the connectedness of subsystems in the prostate network following ERK and/or Akt knockdowns we computed synergy coefficients of the form:(15)The quantity denotes the steady-state concentration (flux) of species (interaction) j in wild-type C-81. The quantity () denotes the steady-state concentration (flux) of species (interaction) j in the presence of an Akt (ERK) knock-out minus the basal value of quantity j. The term denotes the steady-state concentration (flux) of species (interaction) j in wild-type C-81. If , the quantity j has a positive synergy with Akt and ERK. In other words, the steady-state concentration (flux) of species (interaction) j in the wild-type was greater than the sum of the individual contributions in single Akt or ERK knock-downouts. Conversely, if , the quantity j has a negative synergy with Akt and ERK. Lastly, if then there is no connection between quantity j and the Akt/ERK signaling axes.
Prostate model interactions and parameters for the C-33, C-51, and C-81 LNCaP clones. The kinetics of binding and catalytic interactions were assumed to follow mass-action rate laws. The quantity kon denotes forward rate constants, koff denotes backward rate constants, and kcat denotes catalytic rate constants. All binding interactions were assumed to be reversible. The citations listed were the primary source of information for the corresponding interaction, and include either the exact interaction (i.e., from preexisting model) or evidence from which the interaction was inferred. Unless otherwise specified, concentration units were arbitrary (A.U) as a result of arbitrary units on training data. Thus, zero-order rate constants had units of A∶Us¡1, first-order rate constants had units of s¡1, and second-order rate constants had units of (A∶U)¡1s¡1 The mean and standard deviation over the parameter ensemble are reported for each kinetic parameter. ¦: The expression of the PAcP isoforms, PSA, and cyclin D was implemented using the same translation/transcription heuristic, save any specific transcription factors. ?: Her2 adaptor complex reactions were taken to be similar those of EGFR (66). y: Inferred from collaboration with Prosetta Cooperation (http://www.prosetta.com/). z: Internalized EGFR complexes were assumed to signal identically to membrane-bound EGFR (30,67).
(0.07 MB XLS)
Experimental training data used to estimate the ensemble of prostate model parameters.
(0.02 MB PDF)
Non-zero initial conditions estimated from the training data for the C-33 LNCaP clone. The mean (μ) and standard deviation (σ) calculated over the ensemble are shown.
(0.03 MB PDF)
Interactions determined to be significantly fragile for the C-33, C-51, and C-81 LNCaP clones. Overall state sensitivity coefficients (OSSCs) were calculated over the parameter ensemble. The OSSC values were ranked ordered. The mean rank and standard deviation for interactions with rank greater than at least one standard deviation above the overall mean rank are reported.
(0.03 MB PDF)
The authors thank the anonymous reviewers for their helpful suggestions. Additionally, we acknowledge the careful review of the manuscript by Prof. Andrew Yen and members of the Yen laboratory.
Conceived and designed the experiments: RAT JDV. Performed the experiments: RAT SN SS PK NR. Analyzed the data: RAT SN SS PK NR. Contributed reagents/materials/analysis tools: SN. Wrote the paper: RAT JDV. Assisted in writing paper and oversaw the experimental designs: JDV.
- 1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43–66.A. JemalR. SiegelE. WardT. MurrayJ. Xu2007Cancer statistics, 2007.CA Cancer J Clin574366
- 2. Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. Cancer Research 293–297.C. HugginsCV Hodges1941Studies on prostatic cancer: I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.Cancer Research293297
- 3. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM (1980) A prostate antigen in sera of prostatic cancer patients. Cancer Res 40: 2428–2432.LD PapsideroMC WangLA ValenzuelaGP MurphyTM Chu1980A prostate antigen in sera of prostatic cancer patients.Cancer Res4024282432
- 4. Kuriyama M, Wang MC, Lee CL, Killian CS, Papsidero LD, et al. (1982) Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst 68: 99–105.M. KuriyamaMC WangCL LeeCS KillianLD Papsidero1982Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.J Natl Cancer Inst6899105
- 5. Sadar MD, Hussain M, Bruchovsky N (1999) Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 6: 487–502.MD SadarM. HussainN. Bruchovsky1999Prostate cancer: molecular biology of early progression to androgen independence.Endocr Relat Cancer6487502
- 6. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036–1042.MA EisenbergerBA BlumensteinED CrawfordG. MillerDG McLeod1998Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.N Engl J Med33910361042
- 7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512.IF TannockR. de WitWR BerryJ. HortiA. Pluzanska2004Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med35115021512
- 8. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240: 889–895.RM Evans1988The steroid and thyroid hormone receptor superfamily.Science240889895
- 9. Carson-Junica MA, Schrader WT, O'Malley BW (1990) Sterioid receptor family: structure and functions. Endocr Rev 11: 201–220.MA Carson-JunicaWT SchraderBW O'Malley1990Sterioid receptor family: structure and functions.Endocr Rev11201220
- 10. McConnell JD (1955) Prostatic growth: new insights into hormonal regulation. Br J Urol 76: 5–10.JD McConnell1955Prostatic growth: new insights into hormonal regulation.Br J Urol76510
- 11. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5: 1921–1930.PH RiegmanRJ VlietstraJA van der KorputAO BrinkmannJ. Trapman1991The promoter of the prostate-specific antigen gene contains a functional androgen responsive element.Mol Endocrinol519211930
- 12. Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20: 3001–3015.EP Gelmann2002Molecular biology of the androgen receptor.J Clin Oncol2030013015
- 13. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, et al. (2002) Establishment and characterization of androgen-independent human prostate cancer lncap cell model. Prostate 50: 222–235.T. IgawaFF LinMS LeeD. KaranSK Batra2002Establishment and characterization of androgen-independent human prostate cancer lncap cell model.Prostate50222235
- 14. Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, et al. (2003) Erbb-2 signaling is involved in regulating psa secretion in androgen-independent human prostate cancer lncap c-81 cells. Oncogene 22: 781–796.MS LeeT. IgawaTC YuanXQ ZhangFF Lin2003Erbb-2 signaling is involved in regulating psa secretion in androgen-independent human prostate cancer lncap c-81 cells.Oncogene22781796
- 15. Feldman BJ, Feldman D (2001) The development of androgen-independent cancer. Nature Rev Cancer 1: 34–45.BJ FeldmanD. Feldman2001The development of androgen-independent cancer.Nature Rev Cancer13445
- 16. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-i, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474–5478.Z. CuligA. HobischMV CronauerC. RadmayrJ. Trapman1994Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-i, keratinocyte growth factor, and epidermal growth factor.Cancer Res5454745478
- 17. Nazareth LV, Weigel NL (1996) Activation of the human androgen receptor through a protein kinase a signaling pathway. J Biol Chem 271: 19900–19907.LV NazarethNL Weigel1996Activation of the human androgen receptor through a protein kinase a signaling pathway.J Biol Chem2711990019907
- 18. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, et al. (1999) From her2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through map kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96: 5458–5463.S. YehHK LinHY KangTH ThinMF Lin1999From her2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through map kinase in prostate cancer cells.Proc Natl Acad Sci U S A9654585463
- 19. Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the her-2/neu tyrosine kinase. Nat Med 5: 280–285.N. CraftY. ShostakM. CareyCL Sawyers1999A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the her-2/neu tyrosine kinase.Nat Med5280285
- 20. Meng TC, Lee MS, Lin MF (2000) Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 19: 2664–2677.TC MengMS LeeMF Lin2000Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells.Oncogene1926642677
- 21. Vihko P (1979) Human prostatic acid phosphatases: purification of a minor enzyme and comparisons of the enzymes. Invest Urol 16: 349–352.P. Vihko1979Human prostatic acid phosphatases: purification of a minor enzyme and comparisons of the enzymes.Invest Urol16349352
- 22. Lin MF, Clinton GM (1988) The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase. Mol Cell Biol 8: 5477–5485.MF LinGM Clinton1988The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase.Mol Cell Biol854775485
- 23. Sinha AA, Gleason DF, Wilson MJ, Wick MR, Reddy PK, et al. (1988) Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the gleason grading system. Prostate 13: 1–15.AA SinhaDF GleasonMJ WilsonMR WickPK Reddy1988Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the gleason grading system.Prostate13115
- 24. Sakai H, Shiraishi K, Minami Y, Yushita Y, Kanetake H, et al. (1991) Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma. Prostate 19: 265–272.H. SakaiK. ShiraishiY. MinamiY. YushitaH. Kanetake1991Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma.Prostate19265272
- 25. Meng TC, Lin MF (1998) Tyrosine phosphorylation of c-erbb-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J Biol Chem 273: 22096–22104.TC MengMF Lin1998Tyrosine phosphorylation of c-erbb-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells.J Biol Chem2732209622104
- 26. Veeramani S, Yuan T, Chen S, Lin F, Petersen JE, et al. (2005) Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocrine-Related Cancer 12: 805–822.S. VeeramaniT. YuanS. ChenF. LinJE Petersen2005Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.Endocrine-Related Cancer12805822
- 27. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, et al. (1983) Lncap model of human prostatic carcinoma. Cancer Res 43: 1809–1818.JS HoroszewiczSS LeongE. KawinskiJP KarrH. Rosenthal1983Lncap model of human prostatic carcinoma.Cancer Res4318091818
- 28. Kholodenko BN, Demin OV, Moehren G, Hoek JB (1999) Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 274: 30169–30181.BN KholodenkoOV DeminG. MoehrenJB Hoek1999Quantification of short term signaling by the epidermal growth factor receptor.J Biol Chem2743016930181
- 29. Huang CY, Ferrell JE (1996) Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 93: 10078–10083.CY HuangJE Ferrell1996Ultrasensitivity in the mitogen-activated protein kinase cascade.Proc Natl Acad Sci U S A931007810083
- 30. (2002) Computational modeling of the dynamics of the map kinase cascade activated by surface and internalized egf receptors. Nat Biotechnol 20: 370–375.2002Computational modeling of the dynamics of the map kinase cascade activated by surface and internalized egf receptors.Nat Biotechnol20370375
- 31. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase akt pathway in human cancer. Nat Rev Cancer 2: 489–501.I. VivancoCL Sawyers2002The phosphatidylinositol 3-kinase akt pathway in human cancer.Nat Rev Cancer2489501
- 32. Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by eif4e inhibitory proteins. Nature 433: 477–480.JD RichterN. Sonenberg2005Regulation of cap-dependent translation by eif4e inhibitory proteins.Nature433477480
- 33. Fussenegger M, Bailey J, Varner J (2000) A mathematical model of caspase function in apoptosis. Nat Biotechnol 18: 768–774.M. FusseneggerJ. BaileyJ. Varner2000A mathematical model of caspase function in apoptosis.Nat Biotechnol18768774
- 34. Schoeberl B, Eichler-Jonsson C, Gilles ED, Müller G (2002) Computational modeling of the dynamics of the map kinase cascade activated by surface and internalized egf receptors. Nat Biotechnol 20: 370–5.B. SchoeberlC. Eichler-JonssonED GillesG. Müller2002Computational modeling of the dynamics of the map kinase cascade activated by surface and internalized egf receptors.Nat Biotechnol203705
- 35. Stelling J, Gilles ED, Doyle F Jr (2004) Robustness properties of circadian clock architectures. Proc Natl Acad Sci U S A 101: 13210–13215.J. StellingED GillesF. Doyle Jr2004Robustness properties of circadian clock architectures.Proc Natl Acad Sci U S A1011321013215
- 36. Queralt E, Lehane C, Novak B, Uhlmann F (2006) Downregulation of pp2a(cdc55) phosphatase by separase initiates mitotic exit in budding yeast. Cell 125: 719–732.E. QueraltC. LehaneB. NovakF. Uhlmann2006Downregulation of pp2a(cdc55) phosphatase by separase initiates mitotic exit in budding yeast.Cell125719732
- 37. Li H, Ung CY, Ma XH, Liu XH, Li BW, et al. (2009) Pathway sensitivity analysis for detecting pro-proliferation activities of oncogenes and tumor suppressors of epidermal growth factor receptor-extracellular signal-regulated protein kinase pathway at altered protein levels. Cancer 115: 4246–4263.H. LiCY UngXH MaXH LiuBW Li2009Pathway sensitivity analysis for detecting pro-proliferation activities of oncogenes and tumor suppressors of epidermal growth factor receptor-extracellular signal-regulated protein kinase pathway at altered protein levels.Cancer11542464263
- 38. Stites EC, Trampont PC, Ma Z, Ravichandran KS (2007) Network analysis of oncogenic ras activation in cancer. Science 318: 463–467.EC StitesPC TrampontZ. MaKS Ravichandran2007Network analysis of oncogenic ras activation in cancer.Science318463467
- 39. Luan D, Zai M, Varner JD (2007) Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol 3: e142.D. LuanM. ZaiJD Varner2007Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies.PLoS Comput Biol3e142
- 40. Song SO, Varner J (2009) Modeling and analysis of the molecular basis of pain in sensory neurons. PLoS One 4: e6758.SO SongJ. Varner2009Modeling and analysis of the molecular basis of pain in sensory neurons.PLoS One4e6758
- 41. Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, et al. (2009) Input-output behavior of erbb signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol 5: 239.WW ChenB. SchoeberlPJ JasperM. NiepelUB Nielsen2009Input-output behavior of erbb signaling pathways as revealed by a mass action model trained against dynamic data.Mol Syst Biol5239
- 42. Helmy M, Gohda J, Inoue JI, Tomita M, Tsuchiya M, et al. (2009) Predicting novel features of toll-like receptor 3 signaling in macrophages. PLoS One 4: e4661.M. HelmyJ. GohdaJI InoueM. TomitaM. Tsuchiya2009Predicting novel features of toll-like receptor 3 signaling in macrophages.PLoS One4e4661
- 43. Selvarajoo K, Takada Y, Gohda J, Helmy M, Akira S, et al. (2008) Signaling flux redistribution at toll-like receptor pathway junctions. PLoS One 3: e3430.K. SelvarajooY. TakadaJ. GohdaM. HelmyS. Akira2008Signaling flux redistribution at toll-like receptor pathway junctions.PLoS One3e3430
- 44. Selvarajoo K, Tomita M, Tsuchiya M (2009) Can complex cellular processes be governed by simple linear rules? J Bioinform Comput Biol 7: 243–268.K. SelvarajooM. TomitaM. Tsuchiya2009Can complex cellular processes be governed by simple linear rules?J Bioinform Comput Biol7243268
- 45. Asthagiri AR, Lauffenburger DA (2001) A computational study of feedback effects on signal dynamics in a mitogen-activated protein kinase (mapk) pathway model. Biotechnol Prog 17: 227–239.AR AsthagiriDA Lauffenburger2001A computational study of feedback effects on signal dynamics in a mitogen-activated protein kinase (mapk) pathway model.Biotechnol Prog17227239
- 46. Brown KS, Hill CC, Calero GA, Myers CR, Lee KH, et al. (2004) The statistical mechanics of complex signaling networks: nerve growth factor signaling. Phys Biol 1: 184–195.KS BrownCC HillGA CaleroCR MyersKH Lee2004The statistical mechanics of complex signaling networks: nerve growth factor signaling.Phys Biol1184195
- 47. Mayawala K, Gelmi CA, Edwards JS (2004) Mapk cascade possesses decoupled controllability of signal amplification and duration. Biophys J 87: L01–2.K. MayawalaCA GelmiJS Edwards2004Mapk cascade possesses decoupled controllability of signal amplification and duration.Biophys J87L012
- 48. Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R, et al. (2005) Control of mapk signalling: from complexity to what really matters. Oncogene 24: 5533–5542.JJ HornbergB. BinderFJ BruggemanB. SchoeberlR. Heinrich2005Control of mapk signalling: from complexity to what really matters.Oncogene2455335542
- 49. Gadkar KG, Varner J, Doyle FJ (2005) Model identification of signal transduction networks from data using a state regulator problem. Syst Biol (Stevenage) 2: 17–30.KG GadkarJ. VarnerFJ Doyle2005Model identification of signal transduction networks from data using a state regulator problem.Syst Biol (Stevenage)21730
- 50. Gennemark P, Wedelin D (2009) Benchmarks for identification of ordinary differential equations from time series data. Bioinformatics 25: 780–786.P. GennemarkD. Wedelin2009Benchmarks for identification of ordinary differential equations from time series data.Bioinformatics25780786
- 51. Bandara S, Schlöder J, Eils R, Bock HG, Meyer T (2009) Optimal Experimental Design for Parameter Estimation of a Cell Signaling Model. PLoS Comput Biol 5: e1000558.S. BandaraJ. SchlöderR. EilsHG BockT. Meyer2009Optimal Experimental Design for Parameter Estimation of a Cell Signaling Model.PLoS Comput Biol5e1000558
- 52. Battogtokh D, Asch DK, Case ME, Arnold J, Schuttler HB (2002) An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of neurospora crassa. Proc Natl Acad Sci U S A 99: 16904–16909.D. BattogtokhDK AschME CaseJ. ArnoldHB Schuttler2002An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of neurospora crassa.Proc Natl Acad Sci U S A991690416909
- 53. Kuepfer L, Peter M, Sauer U, Stelling J (2007) Ensemble modeling for analysis of cell signaling dynamics. Nat Biotech 25: 1001–1006.L. KuepferM. PeterU. SauerJ. Stelling2007Ensemble modeling for analysis of cell signaling dynamics.Nat Biotech2510011006
- 54. Brown KS, Sethna JP (2003) Statistical mechanical approaches to models with many poorly known parameters. Phys Rev E Stat Nonlin Soft Matter Phys 68: 021904.KS BrownJP Sethna2003Statistical mechanical approaches to models with many poorly known parameters.Phys Rev E Stat Nonlin Soft Matter Phys68021904
- 55. Palmer T, Shutts G, Hagedorn R, Doblas-Reyes F, Jung Y, et al. (2005) Representing model uncertainty in weather and climate prediction. Ann Rev Earth and Planetary Sci 33: 163–193.T. PalmerG. ShuttsR. HagedornF. Doblas-ReyesY. Jung2005Representing model uncertainty in weather and climate prediction.Ann Rev Earth and Planetary Sci33163193
- 56. Gutenkunst RN, Waterfall JJ, Casey FP, Brown KS, Myers CR, et al. (2007) Universally sloppy parameter sensitivities in systems biology models. PLoS Comput Biol 3: 1871–1878.RN GutenkunstJJ WaterfallFP CaseyKS BrownCR Myers2007Universally sloppy parameter sensitivities in systems biology models.PLoS Comput Biol318711878
- 57. Lin MF, Lee MS, Garcia-Arenas R, Lin FF (2000) Differential responsiveness of prostatic acid phosphatase and prostate-specific antigen mrna to androgen in prostate cancer cells. Cell Biol Int 24: 681–689.MF LinMS LeeR. Garcia-ArenasFF Lin2000Differential responsiveness of prostatic acid phosphatase and prostate-specific antigen mrna to androgen in prostate cancer cells.Cell Biol Int24681689
- 58. Kim J, Coetzee GA (2004) Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 93: 233–241.J. KimGA Coetzee2004Prostate specific antigen gene regulation by androgen receptor.J Cell Biochem93233241
- 59. Wilkinson MG, Millar JB (2000) Control of the eukaryotic cell cycle by map kinase signaling pathways. FASEB J 14: 2147–2157.MG WilkinsonJB Millar2000Control of the eukaryotic cell cycle by map kinase signaling pathways.FASEB J1421472157
- 60. Barnes-Ellerbe S, Knudsen K, Puga A (2004) 2,3,7,8-tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. MOLECULAR PHARMACOLOGY 66: 502–511.S. Barnes-EllerbeK. KnudsenA. Puga20042,3,7,8-tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation.MOLECULAR PHARMACOLOGY66502511
- 61. Eder I, Culig Z, Ramoner R, Thurnher M, Putz T, et al. (2000) Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. CANCER GENE THERAPY 7: 997–1007.I. EderZ. CuligR. RamonerM. ThurnherT. Putz2000Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.CANCER GENE THERAPY79971007
- 62. Aderem A (2005) Systems biology: its practice and challenges. Cell 121: 511–513.A. Aderem2005Systems biology: its practice and challenges.Cell121511513
- 63. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276–308.CA HeinleinC. Chang2004Androgen receptor in prostate cancer.Endocr Rev25276308
- 64. Igawa T, Lin FF, Rao P, Lin MF (2003) Suppression of lncap prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate 55: 247–258.T. IgawaFF LinP. RaoMF Lin2003Suppression of lncap prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.Prostate55247258
- 65. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, et al. (2006) Combinatorial activities of akt and b-raf/erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 103: 14477–14482.H. GaoX. OuyangWA Banach-PetroskyWL GeraldMM Shen2006Combinatorial activities of akt and b-raf/erk signaling in a mouse model of androgen-independent prostate cancer.Proc Natl Acad Sci U S A1031447714482
- 66. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, et al. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase ii trial. Prostate 60: 332–337.A. ZiadaA. BarqawiLM GlodeM. Varella-GarciaF. Crighton2004The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase ii trial.Prostate60332337
- 67. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, et al. (2005) Randomized phase ii study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the national cancer institute of canada-clinical trials group. J Clin Oncol 23: 455–460.CM CanilMJ MooreE. WinquistT. BaetzM. Pollak2005Randomized phase ii study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the national cancer institute of canada-clinical trials group.J Clin Oncol23455460
- 68. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, et al. (2008) eif4e knockdown decreases breast cancer cell growth without activating akt signaling. Mol Cancer Ther 7: 1782–1788.A. SoniA. AkcakanatG. SinghD. LuyimbaziY. Zheng2008eif4e knockdown decreases breast cancer cell growth without activating akt signaling.Mol Cancer Ther717821788
- 69. Nayak S, Salim S, Luan D, Zai M, Varner JD (2008) A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials. PLoS ONE 3: e2016.S. NayakS. SalimD. LuanM. ZaiJD Varner2008A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials.PLoS ONE3e2016
- 70. Lukas J, Bartkova J, Bartek J (1996) Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin d-cyclin-dependent kinase-prb-controlled g1 checkpoint. Mol Cell Biol 16: 6917–6925.J. LukasJ. BartkovaJ. Bartek1996Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin d-cyclin-dependent kinase-prb-controlled g1 checkpoint.Mol Cell Biol1669176925
- 71. Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, et al. (2006) Cyclin d1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A 103: 2190–2195.CJ BurdCE PetreLM MoreyY. WangMP Revelo2006Cyclin d1b variant influences prostate cancer growth through aberrant androgen receptor regulation.Proc Natl Acad Sci U S A10321902195
- 72. Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin d1 ablation. Nature 411: 1017–1021.Q. YuY. GengP. Sicinski2001Specific protection against breast cancers by cyclin d1 ablation.Nature41110171021
- 73. (2006) Transcriptional profiling identifies cyclin d1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 66: 11389–11398.2006Transcriptional profiling identifies cyclin d1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.Cancer Res661138911398
- 74. Xu Y, Chen SY, Ross KN, Balk SP (2006) Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin d proteins. Cancer Res 66: 7783–92.Y. XuSY ChenKN RossSP Balk2006Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin d proteins.Cancer Res66778392
- 75. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, et al. (2003) Loss of pten/mmac1/tep in egf receptor-expressing tumor cells counteracts the antitumor action of egfr tyrosine kinase inhibitors. Oncogene 22: 2812–2822.R. BiancoI. ShinCA RitterFM YakesA. Basso2003Loss of pten/mmac1/tep in egf receptor-expressing tumor cells counteracts the antitumor action of egfr tyrosine kinase inhibitors.Oncogene2228122822
- 76. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, et al. (2004) Pten activation contributes to tumor inhibition by trastuzumab, and loss of pten predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127.Y. NagataKH LanX. ZhouM. TanFJ Esteva2004Pten activation contributes to tumor inhibition by trastuzumab, and loss of pten predicts trastuzumab resistance in patients.Cancer Cell6117127
- 77. Sampson ER, Yeh SY, Chang HC, Tsai MY, Wang X, et al. (2001) Identification and characterization of androgen receptor associated coregulators in prostate cancer cells. J Biol Regul Homeost Agents 15: 123–129.ER SampsonSY YehHC ChangMY TsaiX. Wang2001Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.J Biol Regul Homeost Agents15123129
- 78. Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, et al. (2004) Functional domain and motif analyses of androgen receptor coregulator ara70 and its differential expression in prostate cancer. J Biol Chem 279: 33438–33446.YC HuS. YehSD YehER SampsonJ. Huang2004Functional domain and motif analyses of androgen receptor coregulator ara70 and its differential expression in prostate cancer.J Biol Chem2793343833446
- 79. Balk SP, Knudsen KE (2008) Ar, the cell cycle, and prostate cancer. Nucl Recept Signal 6: e001.SP BalkKE Knudsen2008Ar, the cell cycle, and prostate cancer.Nucl Recept Signal6e001
- 80. de Souza PL, Russell PJ, Kearsley J (2009) Role of the akt pathway in prostate cancer. Curr Cancer Drug Targets 9: 163–175.PL de SouzaPJ RussellJ. Kearsley2009Role of the akt pathway in prostate cancer.Curr Cancer Drug Targets9163175
- 81. Los M, Maddika S, Erb B, Schulze-Osthoff K (2009) Switching akt: from survival signaling to deadly response. Bioessays 31: 492–495.M. LosS. MaddikaB. ErbK. Schulze-Osthoff2009Switching akt: from survival signaling to deadly response.Bioessays31492495
- 82. (2006) Expression and nuclear localization of erbb3 in prostate cancer. Clin Cancer Res 12: 2730–2737.2006Expression and nuclear localization of erbb3 in prostate cancer.Clin Cancer Res1227302737
- 83. Cardillo MR, Monti S, Silverio FD, Gentile V, Sciarra F, et al. (2003) Insulin-like growth factor (igf)-i, igf-ii and igf type i receptor (igfr-i) expression in prostatic cancer. Anticancer Res 23: 3825–3835.MR CardilloS. MontiFD SilverioV. GentileF. Sciarra2003Insulin-like growth factor (igf)-i, igf-ii and igf type i receptor (igfr-i) expression in prostatic cancer.Anticancer Res2338253835
- 84. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JMS, et al. (2007) Expression levels of the jak/stat pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 97: 378–383.L. TamLM McGlynnP. TraynorR. MukherjeeJMS Bartlett2007Expression levels of the jak/stat pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer.Br J Cancer97378383
- 85. Dickinson RP, Gelinas RJ (1976) Sensitivity analysis of ordinary differential equation systems—a direct method. J Comp Phys 21: 123–143.RP DickinsonRJ Gelinas1976Sensitivity analysis of ordinary differential equation systems—a direct method.J Comp Phys21123143